Friday, December 23, 2011

Vivus takes heavy hit on obesity drug danger study

Vivus Inc. saw its shares plunge 15 percent Thursday after bad news about an ingredient in its Qnexa obesity drug, now under review by U.S. regulators.
Mountain View-based Vivus (NASDAQ: VVUS) tested topiramate, an ingredient in Qnexa, and found that babies born from moms taking the drug had a higher rate of cleft lip and cleft palate.

No comments:

Post a Comment